Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylstilbestrol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 13/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | FYN | P06241 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylstilbestrol SCHEMBL28055584 | 0.88 | ESR1 (0.78) | ESR1ESR2NR1I2KMT2ASMN1; SMN2 | |
| Diethylstilbestrol SCHEMBL28167476 | 0.88 | ESR1 (0.78) | ESR1ESR2NR1I2KMT2ASMN1; SMN2 | |
| Diethylstilbestrol SCHEMBL27584856 | 0.88 | ESR1 (0.78) | ESR1ESR2NR1I2KMT2ASMN1; SMN2 | |
| Diethylstilbestrol SCHEMBL707842 | 0.88 | ESR1 (0.78) | ESR1ESR2NR1I2KMT2ASMN1; SMN2 | |
| Diethylstilbestrol SCHEMBL9372 | 0.88 | ESR1 (0.78) | ESR1ESR2NR1I2KMT2ASMN1; SMN2 | |
| Diethylstilbestrol SCHEMBL21805900 | 0.87 | ESR1 (0.55) | ESR1ESR2NR1I2KMT2ASMN1; SMN2 | |
| Diethylstilbestrol SCHEMBL28644636 | 0.86 | ESR1 (0.75) | ESR1ESR2NR1I2KMT2ASMN1; SMN2 | |
| SCHEMBL30306312 | 0.86 | BLM (0.67) | ESR1ESR2NR1I2KMT2ASMN1; SMN2 | |
| SCHEMBL9371 | 0.86 | BLM (0.67) | ESR1ESR2NR1I2KMT2ASMN1; SMN2 | |
| SCHEMBL707841 | 0.84 | BLM (0.87) | ESR1ESR2NR1I2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2597 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735116-A2 | ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2025080751-A2 | ANTI-CDH17 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| CN-119505441-A | High impact resistance HPVC power tube and processing technology thereof | 杭州百诺电力科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| WO-2025006846-A2 | ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-01-02 | — | — | WO | claimed |
| CN-115863595-A | Composite cathode material and preparation method and application thereof | 蜂巢能源科技(无锡)有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-105164152-B | GLA domains as targeting agents | 勇士生物科学公司 | 2021-07-06 | — | — | CN | claimed |
| CN-110105020-B | Fair-faced concrete and preparation method thereof | 佛山市政通混凝土有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-110828872-B | High-temperature proton exchange membrane for fuel cell and preparation method thereof | 江苏擎动新能源科技有限公司 | 2021-03-12 | — | — | CN | claimed |
| CN-112159514-A | High-elasticity latex cotton for sofa and preparation method thereof | 东莞戎马家具有限公司 | 2021-01-01 | — | — | CN | claimed |
| WO-2020081329-A1 | METHODS AND COMPOSITIONS FOR MODULATING PCSK9 AND ANGPTL3 EXPRESSION | CAMP4 THERAPEUTICS CORPORATION (US) | 2020-04-23 | — | — | WO | claimed |
| EP-1506285-A2 | COMBINATIONS OF ANTIBODIES SELECTIVE FOR A TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND OTHER THERAPEUTIC AGENTS | UAB RESEARCH FOUNDATION (US) | 2005-02-16 | — | — | EP | claimed |
| WO-2004094649-A2 | TOLERANCE TO GRAFT FOLLOWING THYMIC REACTIVATION | NORWOOD IMMUNOLOGY, LTD. (AU) | 2004-11-04 | — | — | WO | claimed |
| WO-2004094988-A2 | TOLERANCE TO GRAFT PRIOR TO THYMIC REGENERATION | NORWOOD IMMUNOLOGY, LTD. (AU) | 2004-11-04 | — | — | WO | claimed |
| WO-2004094599-A2 | DISEASE PREVENTION AND VACCINATION FOLLOWING THYMIC REACTIVATION | NORWOOD IMMUNOLOGY, LTD. (AU) | 2004-11-04 | — | — | WO | claimed |
| US-20030133932-A1 | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents | UAB RESEARCH FOUNDATION, THE | 2003-07-17 | — | — | US | claimed |
| US-6581606-B2 | Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response | THE RX FILES CORPORATION | 2003-06-24 | — | — | US | claimed |
| WO-2003038043-A2 | COMBINATIONS OF DR5 ANTIBODY AND OTHER THERAPEUTIC AGENTS | UAB RESEARCH FOUNDATION (US) | 2003-05-08 | — | — | WO | claimed |
| EP-1187618-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING POSTMENOPAUSAL AND PERIMENOPAUSAL WOMEN, AND THEIR USE | THE GENERAL HOSPITAL CORPORATION (US) | 2002-03-20 | — | — | EP | claimed |
| WO-2000074684-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING POSTMENOPAUSAL AND PERIMENOPAUSAL WOMEN, AND THEIR USE | THE GENERAL HOSPITAL CORPORATION (US) | 2000-12-14 | — | — | WO | claimed |
| EP-0392745-B1 | Immunoconjugates and prodrugs and their use in association for drug delivery | CELLTECH LTD (GB) | 1994-11-02 | — | — | EP | claimed |